Literature DB >> 193330

Cyclic AMP and metabolic substrates in hemorrhagic shock of the rat.

L O Farnebo, B B Fredholm, B Hamberger, P Hjemdahl, L Westman.   

Abstract

Hemorrhagic shock was induced in rats by bleeding to 35 mmHg for a period of 4 h. Plasma glucose increased rapidly following the onset of bleeding and reached twice the control value after 30 min. After 2 h hypotension the liver content of glycogen was depleted and subsequently the rats became hypoglycemic. The rise in plasma glucose was accompanied by a rise in plasma cyclic AMP, which was 10-fold after 1 h, but returned towards control values at the end of the hypotensive period. There were no corresponding changes in the cyclic AMP contents of liver, heart or adipose tissue. Blood lactate was increased 10-fold and the lactate/pyruvate ratio was more than doubled, suggesting an increased anaerobic metabolism. Plasma FFA levels fell significantly, while plasma glycerol was unchanged during the hypotensive period. In this hemorrhagic shock model there is an initial phase of glucose mobilization from the liver, which is accompanied by elevated plasma cyclic AMP. This phase is followed by a period of depressed levels of glucose as well as FFA and thus a lack of metabolizable substrates in plasma.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 193330

Source DB:  PubMed          Journal:  Acta Chir Scand        ISSN: 0001-5482


  3 in total

1.  Actions of salbutamol in late pregnancy: plasma cyclic AMP, insulin and C-peptide, carbohydrate and lipid metabolites in diabetic and non-diabetic women.

Authors:  B B Fredholm; N O Lunell; B Persson; J Wager
Journal:  Diabetologia       Date:  1978-04       Impact factor: 10.122

2.  Circulating cyclic nucleotides and amines in human cholera.

Authors:  T Morishita; H Asakura; T Hibi; M Tsuchiya; C Uylangco; L Santiago
Journal:  Gastroenterol Jpn       Date:  1981

3.  Vascular and metabolic effects of circulating epinephrine and norepinephrine. Concentration-effect study in dogs.

Authors:  P Hjemdahl; E Belfrage; M Daleskog
Journal:  J Clin Invest       Date:  1979-11       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.